C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on November 20, 2024, regarding events occurring on November 19, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol "CCCC".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
- Board Appointment: On November 19, 2024, the Board appointed Steven L. Hoerter as a director.
- Independence: The Board determined Mr. Hoerter is independent under Nasdaq listing standards.
- Term: Mr. Hoerter is designated as a Class II director, serving until the 2025 Annual Meeting of Stockholders.
- Compensation: Mr. Hoerter was granted stock options to purchase up to 65,000 shares of common stock under the 2020 Stock Option and Incentive Plan.
- Vesting Schedule: One-third of the options vest on the first anniversary of the grant date, with the remainder vesting quarterly over the subsequent two years, contingent on continued service.
- Indemnification: The company entered into a standard indemnification agreement with Mr. Hoerter.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies related to financial operations were disclosed in this report. The appointment was made without any undisclosed arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the independence status of Steven L. Hoerter under Nasdaq listing standards.
- Review the specific terms of the 65,000 share stock option grant and its impact on dilution.
- Confirm the vesting conditions tied to Mr. Hoerter's continued service on the Board.
- Check for any subsequent filings regarding the 2025 Annual Meeting of Stockholders.